Brown Advisory Inc. Purchases 428,996 Shares of Kestra Medical Technologies, Ltd. $KMTS

Brown Advisory Inc. raised its stake in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 34.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,688,356 shares of the company’s stock after acquiring an additional 428,996 shares during the period. Brown Advisory Inc. owned about 2.89% of Kestra Medical Technologies worth $44,775,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies during the 4th quarter valued at $31,000. China Universal Asset Management Co. Ltd. bought a new position in Kestra Medical Technologies during the 3rd quarter valued at $48,000. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies during the 4th quarter valued at $72,000. BNP Paribas Financial Markets lifted its stake in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after acquiring an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the completion of the sale, the insider owned 334,786 shares of the company’s stock, valued at approximately $7,017,114.56. This trade represents a 4.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on KMTS. BTIG Research restated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. Finally, The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $27.40.

Kestra Medical Technologies Trading Down 2.1%

Shares of Kestra Medical Technologies stock opened at $20.41 on Tuesday. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00. The firm has a market cap of $1.19 billion, a PE ratio of -5.15 and a beta of 0.83. The stock has a fifty day moving average price of $20.71 and a 200-day moving average price of $23.03. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business had revenue of $24.55 million for the quarter. The firm’s revenue for the quarter was up 62.7% compared to the same quarter last year. Equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

Kestra Medical Technologies Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.